Dr Jurjees Hasan, Consultant Medical Oncologist
Dr Jurjees Hasan
Consultant Medical Oncologist
About Dr Jurjees Hasan
GMC number: 4784933
Year qualified: 1995
Place of primary qualification: University of Health Sciences
Dr Jurjees Hasan is a distinguished medical oncologist specialising in gynaecological malignancies, colorectal cancer, and carcinoma of unknown primary. He is currently the lead medical oncologist for gynaecological malignancies at The Christie, covering the southern sector of the Greater Manchester Cancer Network.
Dr Hasan graduated in India and subsequently moved to the UK to complete his specialist training. Since his appointment, he has developed a comprehensive chemotherapy service for colorectal cancers. His expertise extends to serving as the principal investigator in phase II and phase III studies of both ovarian and colorectal cancer, as well as in investigator-led studies at The Christie.
In addition to his clinical roles, Dr Hasan is deeply involved in translational research. His research focuses on developing new strategies for managing malignant bowel obstruction, tumour angiogenesis, and circulating biomarkers of angiogenesis. He is also dedicated to the development of anti-angiogenic therapies for cancer.
Dr Hasan's work has been widely recognised, with numerous publications in peer-reviewed journals and presentations at international oncology meetings. He also contributes to the academic community by refereeing manuscripts for oncology journals.
Dr Hasan treats a range of conditions including gynaecological oncology, ovarian cancer, colorectal cancer, and carcinoma of unknown primary. His commitment to advancing cancer treatment and research makes him a leading figure in his field.
Areas of expertise
- Gynaecological malignancies
- Colorectal cancer
- Carcinoma
- unknown primary site
- Gynaecological oncology
Professional memberships
Articles by Dr Jurjees Hasan
Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging
Improved survival from ovarian cancer in patients treated in phase iii trial active cancer centres in the uk
Plasma tie2 is a tumor vascular response biomarker for vegf inhibitors in metastatic colorectal cancer